Long-term outcomes of patisiran for transthyretin-mediated amyloidosis with polyneuropathy

Takeaway

  • Patisiran (PN) appears to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRvPN).

Why this matters

  • ATTRvPN is a rare, progressive disease caused by transthyretin (TTR) gene mutations, whereby misfolded TTR accumulates as amyloid deposits in the organs and tissues; and patisiran (RNA interference agent) inhibits hepatic TTR synthesis, reducing serum levels.

  • The maintained efficacy and safety profile of PN provides a viable treatment option for patients with ATTRvPN, potentially improving quality of life; however, continued long-term surveillance is necessary for overall safety evaluation.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.